

( (S (NP-SBJ-1 Federal health officials)
     (VP are
         (VP expected
	     (S (NP-SBJ *-1)
		(NP-TMP today)
		(VP to
                    (VP approve
                        (NP (NP a program)
                            (VP granting
                                (NP (NP long-deferred access)
				    (PP to 
					(NP (NP the drug)
					    (NP AZT)))
				    (PP for 
					(NP (NP children)
					    (PP with
						(NP acquired immune deficiency syndrome))))))))))))
     .))
( (S (NP-SBJ-2 (NP Announcement)
	       (PP of
		   (NP the approval)))
     (VP is
         (VP expected
             (S (NP-SBJ-1 *T*-2)
                (VP to
                    (VP be
                        (VP made
                            (NP *-1)
                            (PP by
                                (NP-LGS (NP Louis Sullivan)
					,
					(NP (NP secretary)
					    (PP of
						(NP Health and Human Services)))))))))))
     .))
( (S (NP-SBJ (NP The clearance)
             (PP by
                 (NP the Food and Drug Administration)))
     (VP comes
         (PP-TMP after
		 (NP (NP two years)
		     (PP of
			 (NP (NP restricted access)
			     (PP for
				 (NP (NP the youngest victims)
				     (PP of
					 (NP AIDS))))
			     (PP to
				 (NP (NP the only antiviral drug)
				     (VP (ADVP-TMP yet)
					 cleared
					 (S (NP-SBJ *)
					    (VP to
						(VP treat
						    (NP the fatal disease))))))))))))
     .))
( (S (NP-SBJ-1 The drug)
     (VP will
         (VP be
             (VP given
                 (NP *-1)
                 (NP (NP treatment investigational new drug status)
                     ,
                     (NP (NP a label)
                         (VP accorded
                             (NP *)
                             (PP-DTV to 
				     (NP (NP drugs)
					 (VP (VP believed 
						 (S (NP-SBJ *) 
						    (ADJP-PRD effective))) 
					     but
					     (VP lacking
						 (NP formal approval)))))))))))
     .))
( (S (NP-SBJ The move)
     (VP will
         (VP make
             (S (NP-SBJ the drug)
		(ADJP-PRD available
			  (ADVP free 
				(PP of
				    (NP charge)))
			  (PP-TMP for 
				  (NP a time))
			  (PP to
			      (NP (NP children)
				  (PP with
				      (NP (NP the disease)
					  and
					  (NP (NP symptoms)
					      (PP of
						  (NP advanced infection)))))))))))
     .))
( (S (NP-SBJ (NP Adults)
             (PP with
                 (NP AIDS)))
     (VP have
         (VP had
             (NP (NP access)
                 (PP to
                     (NP AZT)))
	     (SBAR-TMP since
		       (S (NP-SBJ FDA)
			  (VP approved
			      (NP (NP (NP the drug 's)
				      usage)
				  (PP for
				      (NP adults)))
			      (PP-TMP in
				      (NP March 1987)))))))
     .))
( (S But
     (PP despite
         (NP (NP (QP more than two)
		 years)
             (PP of
                 (NP (NP research)
                     (VP showing
                         (SBAR 0
                               (S (NP-SBJ AZT)
                                  (VP can
                                      (VP relieve
                                          (NP (NP dementia)
                                              and
                                              (NP other symptoms))
					  (PP in
					      (NP children)))))))))))
     ,
     (NP-SBJ the drug)
     (ADVP-TMP still)
     (VP lacks
         (NP (NP federal approval)
             (PP for
                 (NP (NP use)
                     (PP in
                         (NP the youngest patients))))))
     .))
( (S (PP-PRP As 
	     (NP a result))
     ,
     (S (NP-SBJ-1 many youngsters)
        (VP have
            (VP been
                (ADJP-PRD unable
			  (S (NP-SBJ *-1)
			     (VP to
				 (VP obtain
				     (NP the drug))))))))
     and
     (S ,
        (PP for
            (NP the few exceptions))
        ,
        (NP-SBJ insurance carriers)
        (VP wo n't
            (VP cover
                (NP (NP its cost)
                    (PP of
                        (NP (NP $ 6,400 *U*)
                            (NP-ADV a year)))))))
     .))
( (S (ADVP-TMP So far) 
     ,
     (NP-SBJ AIDS)
     (VP has
         (VP stricken
             (NP (NP 1,859 children)
                 (PP under
                     (NP age 13)))
	     ,
	     (SBAR-ADV with
		       (S (NP-SBJ (QP many times)
				  that number)
			  (VP believed
			      (S (NP-SBJ *)
				 (VP to
				     (VP carry
					 (NP the infection)
					 (PP-MNR without
						 (NP symptoms))))))))))
     .))
( (S (PP-TMP To
	     (NP date))
     ,
     (NP-SBJ (NP 1,013) 
             (PP of
                 (NP those children)))
     (VP have
         (VP died
	     ,
	     (PP according
		 (PP to
		     (NP (NP the federal Centers) 
			 (PP for
			     (NP Disease Control)))))))
     .))
( (S (NP-SBJ (NP Mothers)
             (PP of
                 (NP young AIDS patients)))
     (VP expressed
         (NP somber satisfaction))
     .))
( (S ``
     (NP-SBJ *)
     (VP Thank
         (NP-CLR goodness)
         (SBAR 0
               (S (NP-SBJ it)
                  (VP 's
                      (VP happening)))))
     .))
( (SINV (S-TPC-2 (NP-SBJ It)
		 (VP should
		     (VP have
			 (VP happened
			     (ADVP-TMP sooner)))))
	, ''
	(VP said
	    (S *T*-2))
	(NP-SBJ (NP Elizabeth Glaser)
		,
		(NP (NP a Los Angeles mother and activist)
		    (SBAR (WHNP-1 who)
			  (S (NP-SBJ *T*-1)
			     (VP (VP contracted
				     (NP the AIDS virus)
				     (PP-MNR through
					     (NP a blood transfusion)))
				 , and
				 (VP transmitted
				     (NP it)
				     (PP-CLR to
					     (NP (NP two) 
						 (PP of
						     (NP her children))))))))))
	.))
( (S (NP-SBJ (NP (NP One)
                 (PP of
                     (NP them)))
             ,
             (NP (NP a daughter)
                 (NP Ariel))
             ,)
     (VP died
         (ADVP-TMP (NP a year)
		   ago)
         (PP at 
	     (NP age seven))
	 (SBAR-TMP after
		   (S (NP-SBJ her parents)
		      (ADVP unsuccessfully)
		      (VP pleaded
			  (PP-CLR for
				  (NP the drug))))))
     .))
( (SINV ``
	(S-TPC-2 (NP-SBJ I)
		 (VP could
		     (VP get
			 (NP AZT))))
	, ''
	(VP says
	    (S *T*-2))
	(NP-SBJ (NP Mrs. Glaser)
		,
		(SBAR (WHNP-1 who)
		      (S (NP-SBJ *T*-1)
			 (VP bears
			     (NP her infection)
			     (PP-MNR without
				     (NP any symptoms))))))
	.))
( (S `` But
     (NP-SBJ my daughter)
     (VP could n't
	 (VP *?*)
	 ,
	 (SBAR-TMP until 
		   (S (NP-SBJ she)
		      (VP was
			  (ADJP-PRD too ill
				    (S (NP-SBJ *) 
				       (VP to
					   (VP take
					       (NP it)))))))))
     .))
( (S (S-SBJ (NP-SBJ *)
	    (VP To
		(VP watch
		    (S (NP-SBJ your child)
		       (VP die)))))
     (VP is
         (NP-PRD an inhuman experience))
     . ''))
( (S (NP-SBJ-1 Her son)
     ,
     (S-ADV (NP-SBJ *-1)
	    (ADJP-PRD healthy and symptom-free))
     ,
     (ADVP-TMP currently) 
     (VP takes
         (NP no medication))
     .))
( (S (NP-SBJ-1 (NP The delay)
               (PP in
                   (S-NOM (NP-SBJ *)
			  (VP getting
			      (NP AZT)
			      (PP-DTV to
				      (NP children))))))
     (VP has
         (VP been
             (VP blamed
                 (NP *-1)
                 (PP-CLR on
			 (NP (NP a combination)
			     (PP of
				 (NP factors)))))))
     .))
( (S (ADVP Traditionally)
     ,
     (NP-SBJ-1 the medical establishment)
     (VP has
         (VP waited
             (NP two years)
             (S-CLR (NP-SBJ *-1)
		    (VP to
			(VP approve
			    (NP adult treatments)
			    (PP-CLR for
				    (NP pediatric uses)))))
	     ,
	     (PP-PRP because of
		     (NP (NP a combination)
			 (PP of
			     (NP (NP conservative safety standards)
				 and
				 (NP red tape)))))))
     .))
( (S (ADVP Secondly)
     ,
     (NP-SBJ critics)
     (VP have
         (VP charged
             (NP (NP (NP AZT 's)
                     maker)
                 (NP Burroughs Wellcome Co.))
             (PP-CLR with
		     (NP (NP corporate inertia)
			 (SBAR-PRP because 
				   (S (NP-SBJ children)
				      (VP account
					  (PP-CLR for
						  (NP (NP (NP just 1 %)
							  (PP of
							      (NP the patient population)))
						      and 
						      (ADVP hence) 
						      (NP (NP a small part)
							  (PP of
							      (NP the
								  (ADJP large and lucrative)
								  market))))))))))))
     .))
( (S (NP-SBJ-1 Wellcome)
     (VP has
         (VP (VP replied
                 (SBAR that
                       (S (NP-SBJ-2 it)
                          (VP is
                              (VP moving
                                  (ADVP-DIR ahead)
				  (S-PRP (NP-SBJ *-2)
					 (VP to
					     (VP compile
						 (NP the relevant data)))))))))
             , and
             (VP (ADVP-TMP recently)
                 promised
                 (S (NP-SBJ *-1)
                    (VP to
                        (VP develop
                            (NP (NP a pediatric syrup form)
                                (ADJP easier
                                      (SBAR (WHNP-3 0) 
					    for
					    (S (NP-SBJ youngsters)
					       (VP to
						   (VP take
						       (NP *T*-3)))))))))))))
     .))
( (S (ADVP-TMP Still)
     ,
     (NP-SBJ all this)
     (VP comes
         (SBAR-TMP (NP nearly a year and a half) 
		   after
		   (S (NP-SBJ (NP Philip Pizzo)
			      (PP of
				  (NP the National Cancer Institute)))
		      (VP offered
			  (NP evidence
			      (SBAR that
				    (S (NP-SBJ-1 AZT)
				       (VP could
					   (VP reverse
					       (NP (NP the ravages)
						   (PP of
						       (NP AIDS dementia)))
					       ,
					       (S-ADV (NP-SBJ *-1)
						      (ADVP-TMP sometimes)
						      (VP prompting
							  (NP (NP (NP dramatic recovery)
								  (PP of
								      (NP IQ levels)))
							      and
							      (NP (NP reappearance)
								  (PP of
								      (NP lost motor skills)))))))))))))))
     .))
( (S (PP-TMP Since
	     (NP then))
     ,
     (NP-SBJ (QP roughly 50)
	     pediatric patients)
     (VP have
         (VP received
             (NP the drug)
	     (PP-LOC in 
		     (NP his program))))
     .))
( (S (PP To
         (NP some mothers))
     ,
     (NP-SBJ the expected FDA action)
     (VP is
         (NP-PRD (NP a poignant reminder)
		 (PP of
		     (SBAR-NOM (WHNP-1 what)
			       (S (NP-SBJ *T*-1)
				  (VP might
				      (VP have
					  (VP been))))))))
     .))
( (S ``
     (NP-SBJ My first reaction)
     (VP is
         (SBAR-PRD 0
		   (S (NP-SBJ I)
		      (VP do n't
			  (VP understand
			      (SBAR (WHADVP-1 why)
				    (S (NP-SBJ it)
				       (VP 's
					   (VP taken
					       (ADVP-TMP-CLR so long) 
					       (ADVP-PRP *T*-1))))))))))
     .))
( (SINV (SBARQ-TPC-4 (WHADVP-3 Why)
		     (SQ has
			 (NP-SBJ (NP it)
				 (SBAR *EXP*-1))
			 (VP taken
			     (NP people) 
			     (ADVP-TMP-CLR so long) 
			     (SBAR-1 for
				     (S (NP-SBJ people)
					(VP to
					    (VP understand
						(SBAR 0
						      (S (NP-SBJ pediatric AIDS)
							 (VP is
							     (NP-PRD a major problem))))))))
			     (ADVP-PRP *T*-3)))
		     ? '')
	(VP asked
	    (SBARQ *T*-4))
	(NP-SBJ (NP Helen Kushnick)
		,
		(SBAR (WHNP-2 (WHNP whose son)
			      (NP Samuel))
		      (S (NP-SBJ-5 *T*-2)
			 (VP died
			     (ADVP-TMP (NP six years)
				       ago)
			     (PP at 
				 (NP age three))
			     ,
			     (S-ADV (NP-SBJ *-5) 
				    (NP-PRD (NP victim)
					    (PP of
						(NP a tainted transfusion))))))))
	.))
( (S (NP-SBJ-2 Similar sentiments)
     (VP were
         (VP voiced
             (NP *-2)
	     (PP-LOC on
		     (NP Capitol Hill))))
     .))
( (SINV ``
	(S-TPC-2 (SBAR-ADV While
			   (S (NP-SBJ I)
			      (VP 'm
				  (ADJP-PRD pleased
					    (SBAR 0
						  (S (NP-SBJ the FDA)
						     (VP is
							 (ADVP-TMP finally) 
							 (VP releasing
							     (NP AZT)
							     (PP for
								 (NP children))))))))))
		 ,
		 (NP-SBJ (NP it)
			 (S *EXP*-1))
		 (VP 's
		     (VP taken
			 (ADVP-TMP-CLR much too long) 
			 (S-1 (NP-SBJ *)
			      (VP to
				  (VP get
				      (PP-DIR to
					      (NP this point))))))))
	, ''
	(VP said
	    (S *T*-2))
	(NP-SBJ Rep. Ted Weiss)
	.))
( (S (SBARQ-TPC-1 ``
		  (WHADVP Why)
		  (SQ did
		      (NP-SBJ (NP it)
			      (S *EXP*-2))
		      (VP take
			  (NP Burroughs Wellcome) 
			  (ADVP-TMP-CLR so long) 
			  (S-2 (NP-SBJ *)
			       (VP to
				   (VP apply
				       ''
				       (PP-CLR for
					       (NP treatment investigational new drug status)))))))
		  ?)
     (NP-SBJ the New York Democrat)
     (VP asked
	 (SBARQ *T*-1))
     .))
( (S ``
     (S-TPC-2 (NP-SBJ *)
	      (VP Let
		  (S (NP-SBJ 's)
		     not
		     (VP forget
			 (SBAR 0
			       (S (NP-SBJ this)
				  (VP is
				      (NP-PRD (NP the same company)
					      (SBAR (WHNP-1 that)
						    (S (NP-SBJ *T*-1)
						       (VP has
							   (VP been
							       (VP profiteering
								   (PP-MNR with
									   (NP this drug))
								   (PP-TMP for
									   (NP (QP 2 1) years)))))))))))))))
     , ''
     (NP-SBJ Mr. Weiss)
     (VP added
	 (S *T*-2))
     .))
( (S (NP-SBJ (NP Mrs. Glaser)
             ,
             (SBAR (WHNP-1 who)
                   (S (NP-SBJ *T*-1)
                      (VP is
                          (NP-PRD (NP a co-founder)
				  (PP of
				      (NP (NP the Pediatric AIDS Foundation)
					  ,
					  (VP based
					      (NP *)
					      (PP-LOC-CLR in
							  (NP (NP Santa Monica)
							      ,
							      (NP Calif.)
							      ,))))))))))
     (VP condemned
         (NP (ADJP neither bureaucratic nor corporate) foot-dragging))
     .))
( (S ``
     (S-TPC-3 (NP-SBJ There)
	      (VP 's
		  (NP-PRD (NP no finger)
			  (SBAR (WHNP-2 0)
				(S (NP-SBJ-1 *T*-2)
				   (VP to
				       (VP be
					   (VP pointed
					       (NP *-1)))))))))
     , ''
     (NP-SBJ she)
     (VP said
	 (S *T*-3))
     .))
( (S ``
     (NP-SBJ The crucial thing)
     (VP is
         (UCP-PRD (SBAR that
			(S (NP-SBJ we)
			   (VP learn
			       (NP our lesson)
			       (ADVP-MNR well))))
		  , and
		  (S (NP-SBJ *)
		     (VP to
			 (VP make 
			     (S (ADJP-PRD sure )
				(SBAR-NOM-SBJ 0
					      (S (NP-SBJ (NP other experimental drugs)
							 ,
							 (PP like
							     (NP (NP Bristol-Myers Co. 's)
								 DDI))
							 ,)
						 (VP do n't
						     (VP follow
							 (NP (NP the same frustrating course)
							     (PP as
								 (NP AZT)))))))))))))
     . ''))
( (S (NP-SBJ (NP AIDS dementia)
             (PRN --
		  (SBAR (WHNP-1 which)
			(S (NP-SBJ *T*-1)
			   (ADVP-MNR gradually)
			   (VP steals
			       (NP (NP children 's)
				   ability
				   (S (NP-SBJ *)
				      (VP to
					  (VP speak , walk and think)))))))
		  --))
     (VP is
         (ADVP-TMP often)
         (NP-PRD (NP the
		     (ADJP most striking)
		     aspect)
		 (PP of
		     (NP the pediatric syndrome))))
     .))
( (S (PP For
         (NP some patients))
     ,
     (NP-SBJ AZT)
     (VP has
         (VP restored
             (NP the ability
                 (S (NP-SBJ *)
                    (VP to
                        (VP (VP ride
                                (NP a bicycle))
                            or
                            (VP solve
                                (NP puzzles))))))
	     ,
	     (S-ADV (NP-SBJ *)
		    (VP giving
			(PRT back)
			(NP (NP a piece)
			    (PP of
				(NP their childhood)))
			(SBAR-ADV if
				  (FRAG (ADVP only temporarily)))))))
     .))
( (SINV ``
	(S-TPC-1 (NP-SBJ (NP It)
			 (S *EXP*-3))
		 (VP 's
		     (ADJP-PRD impossible)
		     (S-3 (NP-SBJ *)
			  to
			  (VP overstate
			      (SBAR (WHNP-4 how much)
				    (S (NP-SBJ this)
				       (VP means
					   (NP *T*-4)
					   (PP-CLR to
						   (NP (NP the families)
						       (PP of
							   (NP these patients)))))))))))
	, ''
	(VP said
	    (S *T*-1))
	(NP-SBJ (NP Samuel Broder)
		,
		(NP (NP (NP director)
			(PP of
			    (NP the National Cancer Institute)))
		    and
		    (NP (NP a main developer)
			(PP of
			    (NP AZT)))))
	.))
